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Objectives We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart
failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study.
Background Full adrenergic blockade by carvedilol and additional (e.g., antioxidative) properties may lead to vascular protec-
tion relative to beta-1 blockade alone, and contribute to its efficacy in HF treatment.
Methods Three thousand twenty-nine patients with HF due to ischemic (51%) or idiopathic cardiomyopathy (44%) were ran-
domized double-blind to carvedilol (n 1,511) or metoprolol (n  1,518) and followed for 58 months. Vascular end
points were cardiovascular death, stroke, stroke death, myocardial infarction (MI), and unstable angina.
Results The effect of carvedilol on cardiovascular death improved consistently in subgroups with prespecified baseline vari-
ables. Myocardial infarctions were reported in 69 carvedilol and 94 metoprolol patients (hazard ratio [HR] 0.71, 95%
confidence interval [CI] 0.52 to 0.97, p 0.03). Cardiovascular death or nonfatal MI combined were reduced by 19%
in carvedilol (HR 0.81, 95% CI 0.72 to 0.92, p 0.0009 vs. metoprolol). Unstable angina was reported as an adverse
event in 56 carvedilol and in 77 metoprolol patients (HR 0.71, 95% CI 0.501 to 0.998, p 0.049). A stroke occurred
in 65 carvedilol and 80metoprolol patients (HR 0.79, 95% CI 0.57 to 1.10). Stroke or MI combined occurred in 130 carve-
dilol and 168metoprolol patients (HR 0.75, 95% CI 0.60 to 0.95, p 0.015), and fatal MI or fatal stroke occurred in 34
carvedilol and in 72metoprolol patients (HR 0.46, 95% CI 0.31 to 0.69, p 0.0002). Death after a nonfatal MI or stroke
occurred in 61 of 124 carvedilol and in 106 of 160metoprolol patients (HR 0.66, 95% CI 0.48 to 0.90, p 0.0086).
Conclusions Carvedilol improves vascular outcomes better than metoprolol. These results suggest a ubiquitous protective
effect of carvedilol against major vascular events. (J Am Coll Cardiol 2007;49:963–71) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.059i
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Fhe benefits of beta-blockade in the treatment of heart
ailure (HF) are well established. In addition to angiotensin-
onverting enzyme (ACE) inhibitors, beta-blocking drugs
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of beta-blocking drugs, and are
likely to contribute to their clinical
benefit (5,6). In the COMET
(Carvedilol Or Metoprolol Eu-
ropean Trial) study, carvedilol
improved survival and cardiovas-
cular hospitalizations more than
the beta-1 selective beta-blocker
metoprolol tartrate (7). Carve-
dilol blocks both the beta-1 and
-2 receptor, and has tighter,
more prolonged binding proper-
ties to the beta-1 receptor than
etoprolol, which results in a greater sympatho-inhibitory
ctivity than with metoprolol at the dosages used in the
OMET study (8). Binding of carvedilol to the beta-2
eceptor may have antiarrhythmic effects and may inhibit
yocardial hypertrophy and apoptosis (9,10). Carvedilol
lso blocks alpha 1-adrenergic receptors with enhanced
eripheral vasodilatation and renal sodium excretion (11),
nd has antioxidant and antiendothelin effects. These addi-
ional effects may lead to improved vascular function and
ascular protection relative to the effect of beta-1 selective
lockade alone. The COMET study provided a unique
ossibility to analyze the long-term effects on vascular-
elated outcomes by these agents. In this analysis, we
ompare the effect of carvedilol and metoprolol on vascular
vents in the COMET study.
ethods
he COMET study was a randomized, double-blind,
arallel comparison of carvedilol, 25 mg twice a day, and
etoprolol tartrate, 50 mg twice a day, in patients with
table chronic HF, New York Heart Association (NYHA)
unctional class II to IV and left ventricular dysfunction, in
ddition to standard therapy including ACE inhibition and
iuretics. During an average 58-month follow-up, 1,511
atients received carvedilol and 1,518 patients metoprolol.
tudy design, rationale, inclusion criteria, and main results
ave been published (7,12). Baseline characteristics includ-
ng concomitant medication were comparable between both
tudy groups.
Eligibility criteria included stable HF, NYHA functional
lass II to IV, and a left ventricular ejection fraction (LVEF)
35%. Patients had to be on ACE inhibitor therapy for at
east 4 weeks and receiving diuretics (40 mg furosemide or
quivalent) for at least 2 weeks, and had to have been
ospitalized for cardiovascular reasons at least once in the
ear preceding inclusion.
Patients were excluded if they had hemodynamically
ignificant valvular disease, uncontrolled hypertension, a
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
CI  confidence interval
HF  heart failure
HR  hazard ratio
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
NYHA  New York Heart
Associationecent (2 months) myocardial infarction (MI), unstable cngina, coronary revascularization or stroke, an implantable
ardioverter-defibrillator, or symptomatic or sustained ven-
ricular arrhythmias despite antiarrhythmic drug therapy.
ontraindication to the use of a beta-blocker, requirement
f intravenous inotropic therapy, a recent change in therapy
defined as an introduction of a new therapy for HF or use
f a beta- or alpha-blocking drug in the preceding 2 weeks),
se of a class I antiarrhythmic agent, amiodarone 200 mg,
erapamil or diltiazem, or treatment with an investigational
rug 30 days before inclusion were further exclusion criteria.
Patients were assigned blindly to carvedilol, 3.125 mg
wice a day (n  1,511), or metoprolol tartrate, 5 mg twice
day (n  1,518), at randomization. Study treatment doses
ere doubled every 2 weeks until the target dose of
arvedilol, 25 mg twice a day, or metoprolol, 50 mg twice a
ay, was reached. Dosages could be adapted by the inves-
igator at any time during the study in case of side effects.
he 2 co-primary end points were: 1) all-cause mortality;
nd 2) all-cause mortality or all-cause hospitalization. Sec-
ndary end points included outcome variables used in this
eport (e.g., cardiovascular death and hospitalizations for
onfatal MI and unstable angina). An independent events
ommittee blindly adjudicated each death first into noncar-
iovascular and cardiovascular deaths, and subsequently
ategorized the cardiovascular deaths as sudden death, death
ue to worsening HF, death due to stroke or other cardio-
ascular deaths. The latter comprised deaths due to pulmo-
ary or mesenterial embolism or aortic dissection. The
espective definitions are provided in the Appendix. Con-
equently, all measured outcome variables, except stroke not
eading to death, were prespecified in this analysis.
Death after MI was not considered a separate mode of
eath, but rather an event leading to death. Myocardial
nfarction had to be documented in the case record form by
t least 2 of 4 criteria: chest pain typical of MI for30 min,
ardiac enzymes to2 the upper limit of normal, evolving
lectrocardiogram pattern suggestive of MI, or autopsy
vidence of a recent MI.
For the current analysis, all MIs leading to death were
rouped as fatal MI. Hospitalizations or adverse events
ecording an MI not leading to death were grouped as
onfatal MI.
Unstable angina pectoris was identified by the investigator as
n adverse event in the case record form. Additionally, unstable
ngina could be identified as a cause for hospital admission or
ccurring during hospitalization and had to be confirmed by
he absence of the aforementioned markers of MI.
All cerebrovascular accidents were defined and docu-
ented by the investigator in the case record form. The
iagnosis of nonfatal stroke was provided by the investigator
n the adverse event page of the case record form, whereas
trokes leading to death were adjudicated as stroke death by
he independent events committee.
tatistical analysis. The number of patients with any vas-
ular event was calculated. Differences at baseline between
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March 6, 2007:963–71 Vascular Protection by Carvedilol in HFhose who did or did not experience any vascular event were
ssessed using t tests for continuous variables and chi-square
ests for categorical data.
Each of the vascular outcomes presented in this paper was
alculated from the time of randomization to the time of the
rst event of that type. Patients who did not have an event
ere censored at the last study visit or at the date of death
f the subject died during the study. Kaplan-Meier event
ates were calculated, and differences between the treat-
ents were assessed using Cox proportional hazard models.
e used proportional hazards models with treatment as the
nly independent variable in the model. This is equivalent to
he log-rank test and allowed us to estimate the hazard ratio
HR) and associated 95% confidence intervals (CIs). Kaplan-
eier estimates of the survivor functions were displayed to
haracterize the treatment effects. The end point of death after
onfatal MI or stroke is presented only for those experiencing
ither event. For this end point, the time to event was
alculated from the time of the original event.
esults
ardiovascular events. Cardiovascular events, including
ardiovascular death, fatal or nonfatal MI, fatal or nonfatal
troke, and unstable angina, occurred in 584 patients receiv-
ng carvedilol and 667 patients receiving metoprolol (HR
.85, 95% CI 0.76 to 0.95, p  0.0038). Baseline charac-
eristics of patients with or without a vascular event are
ompared in Table 1. Subjects experiencing an event were
ound to be older; had more advanced HF as shown by
YHA functional classification, duration of HF, and brain
atriuretic peptide levels; a greater percentage of ischemic
tiology of HF as compared with idiopathic dilated cardio-
yopathy; and were more likely to have a history of MI,
oronary interventions, diabetes, hypertension, and stroke.
dditionally, they were treated more often with nitrates and
spirin than patients without an event.
Baseline criteria were similar in both treatment groups
mong those subjects with an event, apart from a slight
ifference in the initial NYHA functional classification
NYHA II/III/IV, carvedilol 36%/59%/5%, metoprolol
9%/53%/8%, p  0.0358).
ardiovascular mortality. Cardiovascular deaths occurred
n 438 (29%) patients receiving carvedilol and in 534 (35%)
atients in the metoprolol group (HR 0.80, 95% CI 0.70 to
.90, p  0.0004). Baseline characteristics were examined,
ut no differences were found between the treatment groups
data not shown).
The superior effect of carvedilol on cardiovascular death
as consistent in subgroups with pre-specified baseline
ariables, such as gender, age ( or 65 years), NYHA
unctional classification, LVEF  or25%, heart rate  or
80 beats/min, history of ischemic heart disease, previous
I, diabetes, angina, hypertension, atrial fibrillation, andeceiving antiplatelet or anticoagulant therapy (Fig. 1). hI. A fatal MI occurred in 21 carvedilol and in 36
etoprolol patients (HR 0.57, 95% CI 0.33 to 0.98, p 
.041) (Fig. 2). This different effect of carvedilol on fatal MI
tarted relatively early, during the first year of treatment
Fig. 3).
When fatal and nonfatal MIs were combined, carvedilol
ignificantly reduced the occurrence of all MIs by 29% (HR
.71, 95% CI 0.52 to 0.97, p  0.033) (Fig. 2).
nstable angina. Unstable angina was reported as an
dverse event in 56 carvedilol patients and in 77 patients
eceiving metoprolol (HR 0.71, 95% CI 0.501 to 0.998, p
.049) (Fig. 2). Hospitalizations for unstable angina were
educed by 17% by carvedilol (HR 0.83, 95% CI 0.64 to
.09, p  0.185).
troke. A stroke was reported in 65 patients in the carve-
ilol group and in 80 patients treated with metoprolol (HR
.79, 95% CI 0.57 to 1.10, p  0.163) (Fig. 2). Baseline
riteria were comparable in both groups with the exception
f patients in the metoprolol group being older than
arvedilol patients (68  9.0 years vs. 65  8.3 years,
espectively, mean  SD, p  0.0075). Fatal strokes
ccurred in 13 carvedilol versus 38 metoprolol patients (HR
.33, 95% CI 0.18 to 0.62, p  0.0006) (Fig. 2).
ffect of carvedilol on combined vascular events. The
ffect of carvedilol on the combined end point of MI or
troke was significant (HR 0.75, 95% CI 0.60 to 0.95, p 
.015), and the effect on fatal MI or fatal stroke was highly
ignificant (HR 0.46, 95% CI 0.31 to 0.69, p  0.0002).
ffect differences started early during the first year of
reatment and remained constant over time (Fig. 3).
Carvedilol reduced the risk of any MI, any unstable
ngina, or any stroke by 19% (p  0.017) (Figs. 2 and 4).
The occurrence of cardiovascular death and nonfatal MI
as significantly reduced by carvedilol (HR 0.81, 95% CI
.72 to 0.92, p  0.0009) as was the combination of
ll-cause mortality and nonfatal MI (HR 0.84, 95% CI 0.75
o 0.94, p  0.0026) (both Fig. 2). Also, cardiovascular
eath, nonfatal MI, or stroke was reduced (HR 0.83, 95%
I 0.74 to 0.94, p  0.0022). Again, changes occurred
arly, and the difference in effect remained constant during
he study (Fig. 5).
The occurrences of cardiovascular death and unstable
ngina or stroke, respectively, were significantly reduced in
avor of carvedilol, as were the combinations of all-cause
eath and unstable angina and all-cause death and stroke
Fig. 2).
ortality after stroke/MI. Death after nonfatal MI or
onfatal stroke occurred in 61 of 124 patients on carvedilol
nd 106 or the 160 patients on metoprolol. This was a
ignificant treatment difference (HR 0.66, 95% CI 0.48 to
.90, p  0.0086) (Fig. 6).
reatment effect on vascular end points in patients with
r without a history of ischemic heart disease. The effect
f carvedilol was comparable in both patients with a history
f ischemic heart disease and in those without such a
istory, albeit that the effect of carvedilol was more robust
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Vascular Protection by Carvedilol in HF March 6, 2007:963–71n some end points (e.g., fatal MI in patients with a history
f ischemic heart disease). However, interaction tests did
ot show a significant difference in study treatment effect
etween the 2 groups for any of the end points. These data
re presented in Table 2.
iscussion
his analysis indicates a consistently greater effect on major
ardiovascular events, including MI, unstable angina,
aseline Characteristics of Patients With or Without a CardiovascuFatal or Nonf tal MI/Fatal or Nonfatal Stroke/Unstable Angin /C
Table 1 Baseline Characteristics of Patients With or Without a(Fatal or Nonfatal MI/Fatal or Nonfatal Stroke/Unstab
Any Event
(n  1,251)
Age (yrs), mean/SD 64.9/10.5
Gender (% male) 80.5
Body mass index (kg/m2), mean/SD 26.4/4.3
Systolic BP (mm Hg), mean/SD 123.8/20.1
Diastolic BP (mm Hg), mean/SD 75.5/11.1
Heart rate (beats/min), mean/SD 80.8/13.2
NYHA functional class, %
II 37.7
III 56.0
IV 6.3
Duration CHF (months) mean/median 51.8/31.0
Etiology CHF,* %
Ischemic heart disease 66.1
Hypertension 18.9
Dilated cardiomyopathy 31.4
LVEF mean/SD 25.4/7.2
NT-proBNP (pg/ml) median 1,871
Previous MI, % 53.5
Current angina, % 27.9
Previous angioplasty, % 9.9
Previous CABG, % 22.2
Hypertension, % 39.3
Diabetes, % 28.9
Stroke, % 8.9
Concomitant medication at randomization, %
Diuretics* 98.9
ACE inhibitors* 90.8
Angiotensin receptor antagonists 6.4
Digitalis 61.3
Antiarrhythmics 14.8
Nitrates 43.0
Aldosterone antagonists 12.7
Beta-blockers† 5.0
Anticoagulants 45.8
Aspirin 42.4
Lipid-lowering agents (statins) 20.9
Laboratory measurements
Hemoglobin level (g/dl) 14.0/1.6
Serum creatinine (mol/l) 115.5/48.8
Blood glucose (mmol/l) 6.9/3.2
Inclusion criteria; †stopped before study start.
ACE angiotensin-converting enzyme; BP blood pressure; BNP brain natriuretic peptide; CA
yocardial infarction; NT-proBNP  N-terminal pro-brain natriuretic peptide; NYHA  New York Htroke, and cardiovascular death, by carvedilol as compared tith metoprolol tartrate. With the exception of hospitaliza-
ion for unstable angina and any strokes, all parameters
easured were significantly reduced by carvedilol. These
esults strongly suggest a protective effect of carvedilol
gainst major vascular events.
As previous analyses have also indicated that carvedilol
educes the occurrence of sudden death and death due to
orsening HF (7), a decrease in ischemic events may well
ontribute to this survival benefit, in addition to other
echanisms including hemodynamic improvement and an-
nd Pointvascular Death)
iovascular End Point
gina/Cardiovascular Death)
No Event
(n  1,778)
Total
(n  3,029) p Value
59.9/11.5 62.0/11.4 0.0001
79.3 79.8 0.4207
27.2/4.5 26.9/4.4 0.0001
127.7/18.9 126.1/19.5 0.0001
78.3/10.6 77.1/10.9 0.0001
81.3/13.4 81.1/13.4 0.2668
55.9 48.4 0.0001
42.1 47.8
2.0 3.8
35.7/15.0 42.4/21.0 0.0001
43.0 52.5 0.0001
16.9 17.7 0.1415
52.7 43.9 0.0001
26.6/7.1 26.1/7.2 0.0001
970.6 1,242 0.0001
33.1 41.5 0.0001
17.2 21.6 0.0001
6.9 8.1 0.0024
13.4 17.0 0.0001
35.2 36.9 0.0201
20.8 24.2 0.0001
5.8 7.1 0.0011
98.6 98.7 0.4903
91.7 91.4 0.3726
6.6 6.5 0.7909
58.1 59.4 0.0763
10.3 12.1 0.0002
25.5 32.8 0.0001
9.4 10.8 0.0044
3.8 4.3 0.1303
45.7 45.7 0.9419
32.9 36.8 0.0001
21.3 21.1 0.7923
14.3/1.5 14.2/1.5 0.0001
101.4/33.5 107.2/41.1 0.0001
6.4/2.7 6.6/2.9 0.0001
oronary bypass surgery; CHF chronic heart failure; LVEF left ventricular ejection fraction; MI
sociation.lar Eardio
Card
le Aniarrhythmic properties of carvedilol (9,13–17).
d
c
w
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March 6, 2007:963–71 Vascular Protection by Carvedilol in HFThe vascular protective effect of carvedilol is probably
ependent on different mechanisms, and the result of its
omplex pharmacologic profile.
Figure 1 Risk of Cardiovascular Death by Subgroups With Pred
Carvedilol consistently improves cardiovascular death compared with metoprolol. a
ECG  electrocardiogram; HR  hazard ratio; IHD  ischemic heart disease; LVEF
Heart Association functional classification.
Figure 2 Effect of Carvedilol Compared With Metoprolol on Sin
With few exceptions, carvedilol (Carv) consistently reduces vascular event risk. AE
CV  cardiovascular; hosp  hospitalization; Meto  metoprolol; other abbreviatioThe vascular endothelium contains both beta-1 and -2 as
ell as alpha-1 receptors. Blockade of all 3 adrenergic
eceptors by carvedilol provides for better endothelium-
d Baseline Variables
rial fibrillation; Asp/anticoag  aspirin/anticoagulant; CI  confidence interval;
t ventricular ejection fraction; MI  myocardial infarction; NYHA  New York
nd Combined Vascular Events
erse event;
in Figure 1.efine
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Vascular Protection by Carvedilol in HF March 6, 2007:963–71ependent vasodilatation than more selective beta-blockade
18). Both in animal and human studies, carvedilol, but not
etoprolol, results in vasodilatation and better improves
ndothelial function (19,20). Also, antioxidative and anti-
poptotic properties of carvedilol may play a role in
mproving free radical-induced endothelial dysfunction,
educe myocardial injury and infarct size after ischemia-
eperfusion, and may affect atherosclerosis formation
Figure 3 Kaplan-Meier Plots of Time to Fatal MI, Any Stroke, F
There were significantly fewer events in the carvedilol group than in the metoprolo
points barring any stroke. The effect of carvedilol started early and was constant o
Figure 4 Kaplan-Meier Curves of the Combined
End Point of any MI, Unstable Angina, and Stroke
Significant greater reduction of the combined end point of any myocardial
infarction (MI), unstable angina, and stroke with carvedilol than with
metoprolol.d21–30). Moreover, carvedilol, but not beta-1 adrenergic
lockade, suppresses norepinephrine release from the
schemic heart, which is likely to contribute to better
nti-ischemic effects, vaso-dynamics, and, possibly,
asculo-protection by the drug (31).
Taken together, the vascular protective and anti-ischemic
ffects observed with carvedilol are likely to contribute to the
linical benefit of the drug in the COMET study, in relation to
he effect of metoprolol. Death in patients with HF is often
inked to an acute ischemic event. Although this is obviously
he case for MI and stroke deaths, sudden death is also
requently the result of an acute coronary ischemic event.
ndeed, in the COMET study, carvedilol significantly reduced
udden death to a larger extent than metoprolol (7).
It has been hypothesized before that that the beneficial
ffects of carvedilol, compared with metoprolol tartrate,
ay be partially explained by a greater degree of blockade
f the beta-1 adrenergic receptors. The greater effect of
arvedilol on heart rate, compared with metoprolol, has
een used to support this hypothesis. However, this
ifference was minimal (1.6 beats/min with carvedilol
ompared with metoprolol) and significant only at 4, 8,
nd 16 months (7).
Moreover, in a post-hoc analysis of our data, the effects of
arvedilol, compared with metoprolol, on outcome were
ndependent of any change in heart rate, and no interaction
ith heart rate, systolic blood pressure, or the beta-blocker
I or Stroke, and Any MI or Stroke in the 2 Treatment Groups
for all these end
e. MI  myocardial infarction.atal M
l group
ver timose was found (32).
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March 6, 2007:963–71 Vascular Protection by Carvedilol in HFWe, therefore, consider the vascular effects of carvedilol the
esult of its specific pharmacologic profile, and not the result of
ore intense beta-1 blockade than metoprolol in our study.
Carvedilol’s vasculo-protective and anti-ischemic proper-
ies are likely to contribute to a greater improvement in
ardiac function in HF than beta-1–selective blocking
gents. Several smaller studies and a recent meta-analysis
ndicate that long-term treatment with carvedilol results in
greater increase in LVEF than metoprolol (13–16).
In the CHRISTMAS (Carvedilol Hibernating Revers-
ble ISchaemia Trial: MArker of Success) study, improve-
Figure 5 Time to CV Death or Nonfatal MI, Death or
Nonfatal MI, CV Death, Nonfatal MI, or Any Stroke
Kaplan-Meier curves for the combined end point of cardiovascular (CV) death
or nonfatal myocardial infarction (MI) (A), all-cause death or nonfatal MI (B),
and CV death, nonfatal MI, or any stroke (C).tent of left ventricular function with carvedilol in patients
ith HF of ischemic origin was greater if more myocardium
as affected by hibernation or ischemia was present (33).
his supports the suggestion that the beneficial effect of
arvedilol in the COMET study may partly be due to its
nti-ischemic properties. The results of the COMET study
ay have a wider application than just to patients with HF.
arvedilol may well be considered the drug of choice in
ther conditions likely to result in or be aggravated by
yocardial ischemic events, whenever the use of beta-
lockade is considered.
tudy limitations. Whereas all fatal events were adjudi-
ated by the events committee in the COMET study,
onfatal events were not. These were classified in a blinded
ashion either from the hospitalization reports or from the
dverse events pages of the case record form if the event had
ot led to hospitalization in the investigator’s own clinic.
vents were only collected for further analysis if a clear
escription was available. However, any hospitalization at
he investigator’s site for an acute MI had to be confirmed
y predefined ECG and enzymatic criteria, and for unstable
ngina by the absence of these criteria. By doing so, we tried
o limit misclassification of nonfatal events as much as
ossible, and this likely contributed to the consistency and
omparable magnitude of treatment effect of carvedilol on
he different fatal and nonfatal vascular events.
onclusions
his present analysis of the COMET study indicates that
arvedilol reduces vascular events, whether fatal or not, to a
reater extent than metoprolol tartrate. The anti-ischemic
roperties of carvedilol can be explained by several mecha-
isms contributing to vasculo-protection by the drug. These
ffects are clinically relevant, and likely to contribute to the
uperior therapeutic profile of this beta-blocker in the
Figure 6 Kaplan-Meier Curves for Death After a Nonfatal
Myocardial Infarction or Nonfatal Stroke
Carvedilol significantly reduces death after a nonfatal
myocardial infarction or stroke compared with metoprolol.reatment of HF.
EA
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Table 2 Events in IHD and Non-IHD Subgroups and Interaction Between Study Medication and Subgroups
Events Carvedilol vs. Metoprolol
Carvedilol Metoprolol HR (95% CI) p Value Interaction p Value
Fatal MI
IHD 17/776 (2.2%) 32/815 (3.9%) 0.55 (0.31–1.00) 0.048 0.509
No IHD 4/735 (0.5%) 4/703 (0.6%) 0.92 (0.23–3.66) 0.900
Any MI
IHD 58/776 (7.5%) 77/815 (9.4%) 0.78 (0.56–1.10) 0.155 0.511
No IHD 11/735 (1.5%) 17/703 (2.4%) 0.59 (0.28–1.25) 0.169
Fatal stroke
IHD 10/776 (1.3%) 23/815 (2.8%) 0.45 (0.21–0.95) 0.035 0.226
No IHD 3/735 (0.4%) 15/703 (2.1%) 0.18 (0.05–0.64) 0.007
Any stroke
IHD 42/776 (5.4%) 53/815 (6.5%) 0.82 (0.55–1.23) 0.329 0.901
No IHD 23/735 (3.1%) 27/703 (3.8%) 0.79 (0.45–1.37) 0.397
Unstable angina AE
IHD 49/776 (6.3%) 65/815 (8.0%) 0.78 (0.54–1.14) 0.197 0.458
No IHD 7/735 (1.0%) 12/703 (1.7%) 0.53 (0.21–1.34) 0.179
Unstable angina hospitalization
IHD 109/776 (14.0%) 122/815 (15.0%) 0.92 (0.71–1.19) 0.540 0.443
No IHD 28/735 (3.8%) 22/703 (3.1%) 1.18 (0.67–2.06) 0.567
Fatal MI  fatal stroke
IHD 27/776 (3.5%) 53/815 (6.5%) 0.53 (0.33–0.84) 0.007 0.374
No IHD 7/735 (1.0%) 19/703 (2.7%) 0.34 (0.14–0.81) 0.014
Any MI  any stroke
IHD 96/776 (12.4%) 124/815 (15.2%) 0.80 (0.61–1.04) 0.099 0.652
No IHD 34/735 (4.6%) 44/703 (6.3%) 0.71 (0.45–1.11) 0.133
Any MI  any stroke  any unstable angina
IHD 174/776 (22.4%) 218/815 (26.7%) 0.82 (0.67–1.00) 0.051 0.753
No IHD 57/735 (7.8%) 60/703 (8.5%) 0.88 (0.61–1.26) 0.475
CV death
IHD 268/776 (34.5%) 348/815 (42.7%) 0.80 (0.68–0.93) 0.005 0.705
No IHD 170/735 (23.1%) 186/703 (26.5%) 0.84 (0.68–1.03) 0.093
Death
IHD 314/776 (40.5%) 381/815 (46.7%) 0.85 (0.73–0.99) 0.033 0.827
No IHD 198/735 (26.9%) 219/703 (31.2%) 0.83 (0.68–1.00) 0.052
CV death  non-fatal MI
IHD 297/776 (38.3%) 372/815 (45.6%) 0.82 (0.71–0.96) 0.013 0.928
No IHD 176/735 (23.9%) 193/703 (27.5%) 0.83 (0.68–1.02) 0.082
Death  non-fatal MI
IHD 340/776 (43.8%) 403/815 (49.4%) 0.87 (0.75–1.00) 0.058 0.665
No IHD 204/735 (27.8%) 226/703 (32.1%) 0.82 (0.68–1.00) 0.046
CV death  any unstable angina
IHD 346/776 (44.6%) 427/815 (52.4%) 0.83 (0.72–0.96) 0.009 0.660
No IHD 191/735 (26.0%) 201/703 (28.6%) 0.87 (0.72–1.07) 0.183
Death  any unstable angina
IHD 389/776 (50.1%) 458/815 (56.2%) 0.87 (0.76–0.99) 0.038 0.835
No IHD 215/735 (29.3%) 234/703 (33.3%) 0.84 (0.70–1.02) 0.073
CV death  any stroke
IHD 287/776 (37.0%) 366/815 (44.9%) 0.81 (0.69–0.95) 0.008 0.535
No IHD 186/735 (25.3%) 195/703 (27.7%) 0.88 (0.72–1.08) 0.209
Death  any stroke
IHD 332/776 (42.8%) 397/815 (48.7%) 0.86 (0.75–1.00) 0.048 0.972
No IHD 213/735 (29.0%) 228/703 (32.4%) 0.86 (0.71–1.04) 0.113
Death post-non-fatal MI or non-fatal stroke
IHD 48/90 (53.3%) 79/117 (67.5%) 0.73 (0.51–1.05) 0.092 0.209
No IHD 13/34 (38.2%) 27/43 (62.8%) 0.48 (0.25–0.94) 0.033
CV death  non-fatal MI  any stroke
IHD 314/776 (40.5%) 390/815 (47.9%) 0.83 (0.72–0.96) 0.014 0.681
No IHD 192/735 (26.1%) 202/703 (28.7%) 0.87 (0.72–1.06) 0.182E  adverse event; CI  confidence interval; CV  cardiovascular; HR  hazard ratio; IHD  ischemic heart disease; MI  myocardial infarction.
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or definitions of the modes of death,
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